Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XLV constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVS | CVS HEALTH CORPORATION | 71.2 | 3.64% | 3.97 | 37 | -11.61% | 26 | distress |
| 2 | GEHC | GE HealthCare Technologies Inc. Common Stock | 69.8 | 8.16% | 0.57 | 37 | -8.78% | 51 | grey |
| 3 | BMY | Bristol-Myers Squibb Co. | 67.2 | 7.36% | 0.66 | 38 | -8.48% | 29 | safe |
| 4 | INCY | Incyte Genomics Inc | 67.1 | 9.16% | 0.33 | 34 | -8.80% | 25 | safe |
| 5 | ZTS | ZOETIS INC. | 66.8 | 9.52% | 0.43 | 37 | -10.03% | 12 | safe |
| 6 | BSX | Boston Scientific Corp. | 64.3 | 5.62% | 0.73 | 36 | -11.08% | 24 | safe |
| 7 | JNJ | Johnson & Johnson | 60.5 | 4.02% | 0.91 | 32 | -6.81% | 54 | safe |
| 8 | COO | The Cooper Companies, Inc. Common Stock | 60.0 | 4.12% | 0.21 | 38 | -17.88% | 73 | safe |
| 9 | ALGN | Align Technology Inc | 58.8 | 6.01% | 0.29 | 37 | -7.56% | 28 | safe |
| 10 | PODD | Insulet Corporation | 58.8 | 5.40% | 0.26 | 36 | -11.02% | 36 | safe |
| 11 | STE | STERIS plc | 58.0 | 5.25% | 0.34 | 36 | -9.03% | 43 | safe |
| 12 | ZBH | Zimmer Biomet Holdings, Inc. | 58.0 | 5.04% | 0.28 | 35 | -11.11% | 22 | safe |
| 13 | REGN | Regeneron Pharmaceuticals Inc | 57.9 | 5.05% | 0.21 | 35 | -11.02% | 46 | safe |
| 14 | ELV | Elevance Health, Inc. | 57.8 | 6.98% | 0.24 | 39 | -4.55% | 12 | safe |
| 15 | RMD | ResMed Inc. | 57.3 | 6.29% | 0.53 | 41 | -6.75% | 21 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | RMD | ResMed Inc. | 57.0 | 9.87% | 11.74 | -6.75% | high |
| 2 | HSIC | Henry Schein Inc | 53.2 | 7.78% | 8.29 | -4.65% | high |
| 3 | INCY | Incyte Genomics Inc | 48.9 | 6.00% | 7.26 | -8.80% | elevated |
| 4 | DVA | DaVita Inc. | 47.6 | 6.90% | 6.75 | +1.28% | elevated |
| 5 | ILMN | Illumina Inc | 44.4 | 7.41% | 5.60 | +30.88% | elevated |
| 6 | BIIB | Biogen Inc. Common Stock | 43.8 | 3.94% | 7.59 | +0.77% | elevated |
| 7 | VEEV | Veeva Systems Inc. | 43.2 | 4.71% | 4.02 | -1.78% | elevated |
| 8 | UHS | Universal Health Services, Inc. Class B | 42.6 | 6.58% | 4.16 | +3.28% | elevated |
| 9 | BDX | Becton, Dickinson and Co. | 41.6 | 4.12% | 7.19 | -5.67% | elevated |
| 10 | SOLV | Solventum Corporation | 40.4 | 3.36% | 5.67 | -3.59% | elevated |
| 11 | HCA | HCA Healthcare, Inc. | 39.7 | 3.68% | 4.52 | +3.45% | elevated |
| 12 | MRNA | Moderna, Inc. Common Stock | 39.2 | 9.10% | 2.53 | +25.50% | elevated |
Market cap, valuation, and short-interest metrics are joined to the latest XLV holdings snapshot; each ticker links to its full quote and analysis page.